Ocugen, Inc.

NASDAQ:OCGN

0.96 (USD) • At close October 29, 2024
Bedrijfsnaam Ocugen, Inc.
Symbool OCGN
Munteenheid USD
Prijs 0.963
Beurswaarde 277,293,611
Dividendpercentage 0%
52-weken bereik 0.351 - 2.105
Industrie Biotechnology
Sector Healthcare
CEO Dr. Shankar Musunuri M.B.A., MBA, Ph.D.
Website https://www.ocugen.com

An error occurred while fetching data.

Over Ocugen, Inc.

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis;

Vergelijkbare Aandelen

AirSculpt Technologies, Inc. logo

AirSculpt Technologies, Inc.

AIRS

6.15 USD

Seer, Inc. logo

Seer, Inc.

SEER

1.98 USD

PetMed Express, Inc. logo

PetMed Express, Inc.

PETS

4.08 USD

Janux Therapeutics, Inc. logo

Janux Therapeutics, Inc.

JANX

54.21 USD

OptimizeRx Corporation logo

OptimizeRx Corporation

OPRX

5.52 USD

MaxCyte, Inc. logo

MaxCyte, Inc.

MXCT

3.57 USD

Affimed N.V. logo

Affimed N.V.

AFMD

3.35 USD

Y-mAbs Therapeutics, Inc. logo

Y-mAbs Therapeutics, Inc.

YMAB

14.74 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)